Prime Medicine Inc (NASDAQ:PRME) shares, rose in value on Wednesday, November 20, with price down by -5.68% to the previous day’s close as strong demand from buyers drove the stock to $2.99.
Actively observing the price movement in the last trading, the stock closed the session at $3.17, falling within a range of $2.9 and $3.19. The value of beta (5-year monthly) was 2.093. Referring to stock’s 52-week performance, its high was $9.86, and the low was $3.06. On the whole, PRME has fluctuated by -32.96% over the past month.
With the market capitalization of Prime Medicine Inc currently standing at about $392.17 million, investors are eagerly awaiting this quarter’s results, scheduled for in December.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that PRME’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of PRME currently trading nearly -23.23% and -21.88% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 31.16, while the 7-day volatility ratio is showing 9.69% which for the 30-day chart, stands at 8.31%. Furthermore, Prime Medicine Inc (PRME)’s beta value is 1.99, and its average true range (ATR) is 0.32.
A comparison of Prime Medicine Inc (PRME) with its peers suggests the former has fared considerably weaker in the market. PRME showed an intraday change of -5.68% in last session, and over the past year, it shrunk by -56.98%%.
Data on historical trading for Prime Medicine Inc (NASDAQ:PRME) indicates that the trading volumes over the past 10 days have averaged 1.35 and over the past 3 months, they’ve averaged 1.51 million. According to company’s latest data on outstanding shares, there are 97.38 million shares outstanding.
Nearly 61.20% of Prime Medicine Inc’s shares belong to company insiders and institutional investors own 39.38% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 15.79 million shares as on 2024-10-31, resulting in a short ratio of 5.78. According to the data, the short interest in Prime Medicine Inc (PRME) stood at 2765.00 of shares outstanding as of 2024-10-31; the number of short shares registered in 2024-09-30 reached 16.72 million. The stock has fallen by -66.25% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the PRME stock heading into the next quarter.
